Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 326

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 326
---
     52 |     17 |      1 |

(f) This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024, it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.) (g ) For 2024 , this line item includes the sale of the Enjaymo global rights to Recordati for pre-tax proceeds of € 768million . For 2023 and 2022 , this line item mainly comprises disposals of assets and activities related to portfolio streamlining, and disposals of equity and debt instruments. (h) For 2022, this line item includes the net cash inflows (before taxes) of € 101million on the divestment of EUROAPI (see Note D.1.). (i) For 2023, this line item includes the net cash outflow on the acquisition of QRIB (see Note D.1.) (j) For 2024, this line item mainly includes a US commercial paper program for € 262million . For 2024 , 2023 and 2022 , it also includes realized foreign exchange differences on (i) cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii) derivative instruments used to manage such cash and cash equivalents.

| F-10 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

Notes to the Consolidated Financial Statements Introduction Sanofi, together with its subsidiaries (collectively “Sanofi”, “the Group” or “the Company”), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY). The consolidated financial statements for the year ended December 31, 2024 , and the notes thereto, were signed off by the Sanofi Board of Directors on February 12, 2025. A/ Basis of preparation A.1. International financial reporting standards (IFRS) The consolidated financial statements cover the twelve-month periods ended December 31,